ASH Annual Meeting

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Use of oral decitabine and cedazuridine vs intravenous/subcutaneous standard-of-care parenteral hypomethylating agents showed similar safety results but also improved treatment in in patients with myelodysplastic syndrome.

Duration of ibrutinib and venetoclax, as determined by the patient’s minimal residual disease, improved survival in patients with treatment-naïve chronic lymphocytic leukemia.

Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.

In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

The use of the experimental navitoclax in combination with ruxolitinib produced impactful results for patients with myelofibrosis.

Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.

Molecular minimal residual disease assessed after chemotherapy induction can identify patients with NPM1-mutated acute monocytic leukemia.

The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.

Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.

Real-world evidence from over 2000 patients with chronic lymphocytic leukemia, over half of whom received prior covalent BTK inhibitor, confirmed the efficacy of venetoclax in pretreated patients.

Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.

Updated results from the phase 1/2 BRUIN study show a high objective response rate and promising progression-free survival outcomes with pirtobrutinib following prior covalent Bruton tyrosine kinase inhibition in patients with chronic lymphocytic leukemia.

Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.

According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Idecabtagene vicleucel improved health-related quality of life compared with standard regimens in patients with triple-class exposed, relapsed/refractory multiple myeloma.

The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.

Evandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Guenther Koehne, MD, PhD, discusses findings from a phase 1/2 trial that are being presented at the American Society of Hematology 2023 Annual Meeting.

Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.

An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

VITAL study results reveal survival advantage of birtamimab for patients with Mayo Stage IV amyloid light chain amyloidosis.